SI2514436T1 - Il-22 for use in treating microbial disorders - Google Patents

Il-22 for use in treating microbial disorders Download PDF

Info

Publication number
SI2514436T1
SI2514436T1 SI200831926T SI200831926T SI2514436T1 SI 2514436 T1 SI2514436 T1 SI 2514436T1 SI 200831926 T SI200831926 T SI 200831926T SI 200831926 T SI200831926 T SI 200831926T SI 2514436 T1 SI2514436 T1 SI 2514436T1
Authority
SI
Slovenia
Prior art keywords
polypeptide
agonist
disease
microbial
ibd
Prior art date
Application number
SI200831926T
Other languages
Slovenian (sl)
Inventor
Alexander R. Abbas
Dimitry M. Danilenko
Sauvage Frederic J. De
Nico P. Ghilardi
Zora Modrusan
Wenjun Ouyang
Patricia A. Valdez
Yan Zheng
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of SI2514436T1 publication Critical patent/SI2514436T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to compositions and methods for treatment of microbial disorder by modulation of the host immune response. More particularly, the present invention relates to compositions that mediate an anti-microbial immune response, and methods of treating a microbial infection using such compositions.

Description

Original document published without description

Claims (7)

IL-22 za uporabo v zdravljenju mikrobnih obolenj Patentni zahtevkiIL-22 for use in the treatment of microbial diseases Patent claims 1. Polipeptid, ki obsega IL-22, za uporabo v postopku zdravljenja mikrobnega obolenja pri subjektu, ki obsega dajanje učinkovite količine polipeptida subjektu, kjer je mikrobno obolenje vnetna črevesna bolezen (IBD, "Inflammatory Bowel Disease").A polypeptide comprising IL-22 for use in a method of treating a microbial disease in a subject comprising administering an effective amount of a polypeptide to a subject in which the microbial disease is Inflammatory Bowel Disease (IBD). 2. IL-22 agonist, ki zviša IL-22 aktivnost, za uporabo v postopku zdravljenja mikrobnega obolenja pri subjektu, ki obsega dajanje učinkovite količine IL-22 agonista subjektu, kjer je mikrobno obolenje IBD, in kjer je IL-22 agonist izbran iz skupine: (a) IL-22-Fc fuzijskega polipeptida (b) IL-22 nukleinske kisline; (c) IL-22 fuzijskega polipeptida; (d) protitelesa ali njegovega biološko aktivnega fragmenta, kjer se protitelo ali fragment veže na IL-22, IL-22R ali IL-22BP; (e) monoklonskega protitelesa, ki se veže na IL-22, IL-22R ali IL-22BP; in (f) humaniziranega protitelesa, ki se veže na IL-22, IL-22R ali IL-22BP.An IL-22 agonist that increases IL-22 activity for use in a method of treating a microbial disease in a subject comprising administering an effective amount of an IL-22 agonist to a subject wherein the IBD is a microbial disease and wherein the IL-22 agonist is selected from groups: (a) IL-22-Fc fusion polypeptide (b) IL-22 nucleic acid; (c) an IL-22 fusion polypeptide; (d) an antibody or a biologically active fragment thereof, wherein the antibody or fragment binds to IL-22, IL-22R or IL-22BP; (e) a monoclonal antibody that binds to IL-22, IL-22R or IL-22BP; and (f) a humanized antibody that binds to IL-22, IL-22R or IL-22BP. 3. Polipeptid ali IL-22 agonist za uporabo po zahtevku 1 ali 2, kjer je dajanje intravensko kot bolus ali kontinuirana infuzija preko časovnega obdobja, intramuskulamo, intraperitonealno, intracerebrospinalno, subkutano, intraartikulamo, intrasinovialno, intratekalno, oralno, topično ali z inhalacijo.The polypeptide or IL-22 agonist for use according to claim 1 or 2, wherein the administration is intravenous as a bolus or continuous infusion over a time period, intramuscularly, intraperitoneally, intracerebrospinal, subcutaneous, intraarticular, intrasinitial, intrathecal, oral, topical or by inhalation. 4. Polipeptid ali IL-22 agonist za uporabo po zahtevku 3, kjer je dajanje intravensko kot bolus ali kontinuirana infuzija preko časovnega obdobja.The polypeptide or IL-22 agonist for use according to claim 3, wherein the administration is intravenously as a bolus or continuous infusion over a time period. 5. Polipeptid ali IL-22 agonist za uporabo po katerem koli od predhodnih zahtevkov, kjer je IBD Crohnova bolezen.The polypeptide or IL-22 agonist for use according to any one of the preceding claims, wherein the IBD is Crohn's disease. 6. Polipeptid ali IL-22 agonist za uporabo po katerem koli od predhodnih zahtevkov, kjer je IBD ulcerozni kolitis.The polypeptide or IL-22 agonist for use according to any one of the preceding claims, wherein the IBD is ulcerative colitis. 7. Komplet za uporabo v postopku za zdravljenje mirkobnega obolenja pri subjektu, kjer komplet obsega farmacevtski sestavek, ki obsega IL-22, in kjer je mikrobna motnja IBD.A kit for use in a method for the treatment of a molar disease in a subject, wherein the kit comprises a pharmaceutical composition comprising IL-22 and wherein the microbial disorder is IBD.
SI200831926T 2007-11-07 2008-11-07 Il-22 for use in treating microbial disorders SI2514436T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US98617007P 2007-11-07 2007-11-07
US1362007P 2007-12-13 2007-12-13
US1562007P 2007-12-20 2007-12-20
EP12169572.0A EP2514436B1 (en) 2007-11-07 2008-11-07 Il-22 for use in treating microbial disorders

Publications (1)

Publication Number Publication Date
SI2514436T1 true SI2514436T1 (en) 2018-04-30

Family

ID=40551983

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200831926T SI2514436T1 (en) 2007-11-07 2008-11-07 Il-22 for use in treating microbial disorders

Country Status (26)

Country Link
US (4) US20090202475A1 (en)
EP (3) EP2514436B1 (en)
JP (3) JP5985150B2 (en)
KR (2) KR101867606B1 (en)
CN (5) CN104888193A (en)
AU (1) AU2008323770B2 (en)
CA (1) CA2705007A1 (en)
CO (1) CO6280406A2 (en)
DK (1) DK2514436T3 (en)
ES (1) ES2662845T3 (en)
HK (2) HK1214137A1 (en)
HR (1) HRP20180445T1 (en)
HU (1) HUE038588T2 (en)
IL (2) IL205623A0 (en)
LT (1) LT2514436T (en)
MX (1) MX2010005108A (en)
NO (1) NO2514436T3 (en)
PH (1) PH12013501074A1 (en)
PL (1) PL2514436T3 (en)
PT (1) PT2514436T (en)
RS (1) RS57021B1 (en)
RU (1) RU2503460C2 (en)
SG (2) SG10202007210RA (en)
SI (1) SI2514436T1 (en)
WO (1) WO2009062102A2 (en)
ZA (1) ZA201003113B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101361968B (en) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 Use of interleukin-22 in treating fatty liver
JP2012507723A (en) * 2008-11-03 2012-03-29 シェーリング コーポレイション Inflammatory bowel disease biomarkers and related treatment methods
WO2011046616A2 (en) * 2009-10-15 2011-04-21 New York University Methods for modulating bacterial infection
US20130130965A1 (en) * 2010-04-08 2013-05-23 University Of Virginia Patent Foundation Method to detect and treat infectious or inflammatory diarrhea based on reg1
CN102260343A (en) 2010-05-25 2011-11-30 健能隆医药技术（上海）有限公司 Application of recombinant human G-CSF dimer for treating nerve damage disease
CN102380091A (en) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 Application of interleukin-22 in curing virus hepatitis
CN103732240B (en) 2011-07-25 2015-12-09 健能隆医药技术（上海）有限公司 The application of G-CSF dimer in preparation treatment neurodegenerative diseases medicine
WO2013085715A1 (en) * 2011-12-05 2013-06-13 The Trustees Of The University Of Pennsylvania Graphene-biomolecule bioelectronic devices
CN102559759A (en) * 2011-12-19 2012-07-11 西安交通大学医学院第一附属医院 HIP/PAP recombinant adenovirus and application thereof in resisting ulcerative colitis
CN103182072B (en) 2011-12-27 2017-05-03 健能隆医药技术（上海）有限公司 Application of interleukin-22 in treating and preventing nerve injuries and neurodegeneration diseases
KR101431324B1 (en) * 2012-08-20 2014-08-20 성균관대학교산학협력단 A pharmaceutical composition comprising a peptide WKYMVm for prevention and treatment of inflammatory bowel diseases
US9314504B2 (en) * 2013-03-14 2016-04-19 Taipei Medical University Use of members of IL-10 cytokine family
DK2970422T3 (en) 2013-03-15 2018-07-16 Hoffmann La Roche IL-22 POLYPEPTIDES AND IL-22 FC-FUSION PROTEINS AND METHODS OF USE
US20160039877A1 (en) 2013-03-15 2016-02-11 Shenzhen Hightide Biopharmaceutical, Ltd. Compositions and methods of using islet neogenesis peptides and analogs thereof
EP3054978B1 (en) 2013-10-08 2019-03-06 Georgia State University Research Foundation, Inc. Compositions including il-18 and il-22 and their use in anti-viral therapies
CN103554267A (en) * 2013-10-15 2014-02-05 山西农业大学 Fusion protein with anti-bacterial function, its construction method and application
JP5515104B1 (en) * 2013-10-25 2014-06-11 独立行政法人農業・食品産業技術総合研究機構 Mycobacterial growth promoter, method for culturing mycobacteria by adding it, and culture medium for acid-fast bacterium containing the same
CN104623637A (en) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Application of IL-22 dimer in preparation of intravenous injection drugs
CN106029100A (en) 2013-11-07 2016-10-12 纪念斯隆–凯特林癌病中心 Methods of use for IL-22 in the treatment of gastrointestinal graft vs. host disease
CN108976289B (en) * 2015-11-20 2021-06-18 深圳市南山区人民医院 Peptide fragment for preventing and treating enteropathogenic escherichia coli infection
WO2017181143A1 (en) 2016-04-15 2017-10-19 Generon (Shanghai) Corporation, Ltd. Use of il-22 in treating necrotizing enterocolitis
KR102482867B1 (en) * 2016-05-18 2023-01-02 모더나티엑스, 인크. Combinations of mRNAs encoding immune modulatory polypeptides and uses thereof
EP4019036A1 (en) * 2017-07-13 2022-06-29 The Healthy Aging Company Reg3alpha for use in the protection of oxygen sensitive gram-positive bacteria
US20220033486A1 (en) * 2018-09-25 2022-02-03 Inserm (Institut National De La Santè Et De La Recherch Médicale) Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
US12029778B2 (en) 2019-05-13 2024-07-09 Yale University Interleukin-18 mimics and methods of use
US20240150453A1 (en) 2021-03-09 2024-05-09 Massachusetts Institute Of Technology Methods of predicting response to anti-tnf blockade in inflammatory bowel disease
CN113304247B (en) * 2021-04-01 2024-03-19 上海市儿科医学研究所 Reg4 protein and application thereof in resisting salmonella enteritidis infection
CN114409758A (en) * 2022-01-24 2022-04-29 上海市儿科医学研究所 Application of Reg4 antibacterial peptide in treatment of pathogenic escherichia coli infection
CN114344451B (en) * 2022-01-25 2023-09-26 上海市肺科医院 Application of Reg4 antibacterial peptide in treatment of pseudomonas aeruginosa infectious pneumonia

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (en) 1978-01-06 1979-08-03 David Bernard DRYER FOR SCREEN-PRINTED SHEETS
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
WO1984003506A1 (en) 1983-03-08 1984-09-13 Commw Serum Lab Commission Antigenically active amino acid sequences
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US5683688A (en) 1984-05-31 1997-11-04 Genentech, Inc. Unglycosylated recombinant human lymphotoxin polypeptides and compositions
NZ215865A (en) 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5571689A (en) 1988-06-16 1996-11-05 Washington University Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE68913658T3 (en) 1988-11-11 2005-07-21 Stratagene, La Jolla Cloning of immunoglobulin sequences from the variable domains
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
DE69029036T2 (en) 1989-06-29 1997-05-22 Medarex Inc SPECIFIC REAGENTS FOR AIDS THERAPY
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0498843B1 (en) 1989-10-24 1996-06-12 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
JP3068180B2 (en) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド Generation of heterologous antibodies
DE69132629T2 (en) 1990-06-27 2002-04-18 Biogen, Inc. SURFACE COMPLEX FORMATION OF LYMPHOTOXIN
CA2086417C (en) 1990-06-29 1999-07-06 Biosource Technologies, Inc. Melanin production by transformed organisms
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (en) 1990-08-29 1997-09-15 Genpharm Int PRODUCTION AND USE OF NON-HUMAN TRANSGENT ANIMALS FOR THE PRODUCTION OF HETEROLOGUE ANTIBODIES
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
CA2090860C (en) 1990-11-21 2003-09-16 Richard A. Houghten Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures
DK0564531T3 (en) 1990-12-03 1998-09-28 Genentech Inc Enrichment procedure for variant proteins with altered binding properties
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
JPH06507398A (en) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Heterogeneous conjugate antibody for treatment of HIV infection
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
WO1994004690A1 (en) 1992-08-17 1994-03-03 Genentech, Inc. Bispecific immunoadhesins
DE69329503T2 (en) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutic use of chimeric and labeled antibodies directed against a differentiation antigen, the expression of which is restricted to human B lymphocyte, for the treatment of B cell lymphoma
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
DE69637481T2 (en) 1995-04-27 2009-04-09 Amgen Fremont Inc. Human antibodies to IL-8 derived from immunized Xenomae
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
AU2660397A (en) 1996-04-05 1997-10-29 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
KR20080059467A (en) 1996-12-03 2008-06-27 아브게닉스, 인크. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
AU757627B2 (en) 1997-06-24 2003-02-27 Genentech Inc. Methods and compositions for galactosylated glycoproteins
ATE419009T1 (en) 1997-10-31 2009-01-15 Genentech Inc METHODS AND COMPOSITIONS CONSISTING OF GLYCOPROTEIN GLYCOFORMS
DE69937291T2 (en) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco ANTIBODY VARIANTS AND FRAGMENTS THEREOF
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK2180007T4 (en) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosylation technique for antibodies to enhance antibody-dependent cell cytotoxicity
US20010023070A1 (en) * 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
US20030003545A1 (en) * 1998-05-29 2003-01-02 Reinhard Ebner Interleukins-21 and 22
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
WO2000039585A1 (en) 1998-12-28 2000-07-06 Sunesis Pharmaceuticals, Inc. Identifying small organic molecule ligands for binding
KR20060067983A (en) 1999-01-15 2006-06-20 제넨테크, 인크. Polypeptide variants with altered effector function
EP2275541B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6939545B2 (en) * 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
US7504256B1 (en) 1999-10-19 2009-03-17 Kyowa Hakko Kogyo Co., Ltd. Process for producing polypeptide
US20030170823A1 (en) * 1999-12-23 2003-09-11 Presnell Scott R. Novel cytokine ZCYTO18
GB0024442D0 (en) * 2000-10-05 2000-11-22 Isis Innovation Genetic factors affecting the outcome of viral infections
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
NZ592087A (en) 2001-08-03 2012-11-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
AU2002337935B2 (en) 2001-10-25 2008-05-01 Genentech, Inc. Glycoprotein compositions
FR2833011B1 (en) * 2001-12-04 2004-10-29 Univ Claude Bernard Lyon NOVEL PROTEIN WITH IL-6 INHIBITING ACTIVITY
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk Process for producing antibody composition
JP4832719B2 (en) 2002-04-09 2011-12-07 協和発酵キリン株式会社 Medicine containing antibody composition for FcγRIIIa polymorphism patients
WO2003085107A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cells with modified genome
ES2362419T3 (en) 2002-04-09 2011-07-05 Kyowa Hakko Kirin Co., Ltd. CELLS WITH DEPRESSION OR DELETION OF THE ACTIVITY OF THE PROTEIN THAT PARTICIPATES IN THE TRANSPORT OF GDP-FUCOSA.
AU2003236017B2 (en) 2002-04-09 2009-03-26 Kyowa Kirin Co., Ltd. Drug containing antibody composition
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO Fc GAMMA RECEPTOR IIIa
EP1499353A4 (en) 2002-04-15 2006-04-05 Human Genome Sciences Inc Antibodies that specifically bind to tl5
EP1539235A2 (en) * 2002-07-01 2005-06-15 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
PT1572744E (en) 2002-12-16 2010-09-07 Genentech Inc Immunoglobulin variants and uses thereof
WO2004058307A1 (en) * 2002-12-18 2004-07-15 Wyeth Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereof
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
KR20060022289A (en) * 2003-06-23 2006-03-09 제네틱스 인스티튜트, 엘엘씨 Antibodies against interleukin-22 and uses therefor
EP2481287B1 (en) * 2003-08-01 2016-07-20 Stratatech Corporation Human skin equivalents expressing exogenous polypeptides
EP1688439A4 (en) 2003-10-08 2007-12-19 Kyowa Hakko Kogyo Kk Fused protein composition
EP1705251A4 (en) 2003-10-09 2009-10-28 Kyowa Hakko Kirin Co Ltd PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY USING RNA INHIBITING THE FUNCTION OF a1,6-FUCOSYLTRANSFERASE
SG10202008722QA (en) 2003-11-05 2020-10-29 Roche Glycart Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
WO2005053742A1 (en) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Medicine containing antibody composition
US20050277593A1 (en) * 2004-05-24 2005-12-15 Washington University Therapeutic uses of Reg protein
RU2302460C1 (en) * 2005-11-02 2007-07-10 Институт цитологии и генетики Сибирского отделения Российской академии наук (СО РАН) RECOMBINANT PLASMID DNA pBi101-IL18 ENCODING HUMAN INTERLEUKIN-18 SYNTHESIS IN TRANSGENIC PLANTS
CN101472611A (en) * 2006-06-19 2009-07-01 惠氏公司 Methods of modulating IL-22 and IL-17

Also Published As

Publication number Publication date
AU2008323770A1 (en) 2009-05-14
US20210338778A1 (en) 2021-11-04
HUE038588T2 (en) 2018-10-29
DK2514436T3 (en) 2018-03-12
JP2015003924A (en) 2015-01-08
IL258730A (en) 2018-06-28
US20090202475A1 (en) 2009-08-13
EP2514436A3 (en) 2013-01-16
HRP20180445T1 (en) 2018-04-20
WO2009062102A2 (en) 2009-05-14
CN104888193A (en) 2015-09-09
RU2010122982A (en) 2011-12-20
KR20100096137A (en) 2010-09-01
EP2217263A2 (en) 2010-08-18
CN108815508A (en) 2018-11-16
PT2514436T (en) 2018-03-21
CA2705007A1 (en) 2009-05-14
MX2010005108A (en) 2010-05-27
AU2008323770A2 (en) 2010-12-09
US20110280828A1 (en) 2011-11-17
NO2514436T3 (en) 2018-05-19
ES2662845T3 (en) 2018-04-10
RU2503460C2 (en) 2014-01-10
KR20160129099A (en) 2016-11-08
SG185972A1 (en) 2012-12-28
JP2016117760A (en) 2016-06-30
KR101867606B1 (en) 2018-06-18
RS57021B1 (en) 2018-05-31
LT2514436T (en) 2018-04-10
EP3360567A1 (en) 2018-08-15
US20130052159A1 (en) 2013-02-28
CN102172395A (en) 2011-09-07
WO2009062102A3 (en) 2009-09-24
HK1214137A1 (en) 2016-07-22
PL2514436T3 (en) 2018-06-29
CN103142999A (en) 2013-06-12
JP6266486B2 (en) 2018-01-24
SG10202007210RA (en) 2020-08-28
EP2514436B1 (en) 2017-12-20
CO6280406A2 (en) 2011-05-20
JP5985150B2 (en) 2016-09-06
ZA201003113B (en) 2015-08-26
CN101951945A (en) 2011-01-19
IL205623A0 (en) 2010-11-30
HK1259102A1 (en) 2019-11-22
AU2008323770B2 (en) 2014-08-07
PH12013501074A1 (en) 2015-01-26
JP2011503102A (en) 2011-01-27
EP2514436A2 (en) 2012-10-24

Similar Documents

Publication Publication Date Title
SI2514436T1 (en) Il-22 for use in treating microbial disorders
HRP20191824T1 (en) Agonistic tnf receptor binding agents
HRP20210393T1 (en) ANTI-TfR ANTIBODIES AND THEIR USE IN TREATING PROLIFERATIVE AND INFLAMMATORY DISORDERS
JP2020511123A5 (en)
HRP20171198T1 (en) Monoclonal antibody against dog interleukin-31
US20230348589A1 (en) Antibodies That Bind Human Cannabinoid 1 (CB1) Receptor
JP2015520758A5 (en)
JP2021063090A (en) Treatment of polybacterial infections
HRP20171931T1 (en) Pharmaceutical formulation comprising a biopharmaceutical drug
JP2018521691A5 (en)
JP2017101068A5 (en)
JP2016533335A5 (en)
HRP20110334T1 (en) Tgf beta 1 specific antibodies
JP6469012B2 (en) Antibodies against interleukin-6 and use thereof
KR102489452B1 (en) Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain
RU2016100892A (en) ANTIBODIES AGAINST TWEAKR AND THEIR APPLICATION
CN110167592A (en) Anti- IL-37 antibody
CN108513615B (en) Antibodies that bind to the human cannabinoid 1(CB1) receptor
CN102791293A (en) Liver targeting molecules
US8795665B2 (en) BMP-6 antibodies
JP2018529635A5 (en)
RU2019102943A (en) ANTIBODY BASED COMPOSITIONS
RU2018121413A (en) Antibody ANTI-PCSK9 and its use
RU2017145662A (en) MONOCLONAL ANTIBODIES AND METHODS OF THEIR APPLICATION
JP2018535961A5 (en)